Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy
These data suggest the potential of the 6-gene Duplex Sequencing assay to improve EGFRi patient selection and therapeutic outcomes.
Authors
- Mingli Yang (ORCID: https://orcid.org/0000-0002-4781-690X)
- Michael J. Hipp (ORCID: https://orcid.org/0000-0003-1904-0670)
- Lance Pflieger (ORCID: https://orcid.org/0000-0003-2237-5674)
- Jake E. Higgins
- W. J. Pledger
- Timothy Joseph Yeatman (ORCID: https://orcid.org/0000-0002-7487-0784)
- Michael J. Schell
- Jesse J. Salk
Institutions
- Buck Institute for Research on Aging (US)
- University of South Florida (US)
- Tampa General Hospital (US)
- Moffitt Cancer Center (US)
- BD Biosciences (United States) (US)
Publication Details
- Journal
- Cellular Oncology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1007/s13402-025-01140-y
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health